The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.

EMS Pharma, whose sister company Novamed bought Takeda’s Multilab last year, is reportedly the front-runner in the bidding process.

Ahead of an aesthetics market battle between Evolus' Jeuveau and Allergan's Botox, Evolus hosted doctors at a conference in Cancun.

Since Nestlé took full control of Galderma in 2014, its skin health unit never really lived up to expectations. And now, the company is bailing.

Civica Rx, a hospital group committed to manufacturing its own drugs, has picked the first drugs it will make and the contractor to make them.

When it comes to CLL, AZ is looking to push Imbruvica aside with newcomer Calquence. But based on some new data, one analyst doesn’t see it happening.

Cancer patients recount stories and offer advice in letters, looking back to when they were first diagnosed, in Merck’s new “With Love, Me” campaign.

AbbVie and Roche’s Venclexta may have recently hit a stumbling block—but in chronic lymphocytic leukemia, it’s rolling.